DERMORPHIN ACETATE

DERMORPHIN ACETATE;L-Tyr-D-Ala-L-Phe-Gly-L-Tyr-L-Pro-L-Ser-NH2;Tyrosyl-alanyl-phenylalanyl-glycyl-tyrosyl-prolyl-serinamide;Dermorphin trifluoroacetate salt

77614-16-5

C40H50N8O10

FHZPGIUBXYVUOY-VWGYHWLBSA-N

802.881

802.365

2SEC01B703

DTXSID40228281

Bulk Drug Intermediates

296

0

white to off-white

1.363±0.06 g/cm3(Predicted)

157-159 °C

-20°C

Triple agonist — GCGR, GIPR, GLP-1R

Investigational (Phase 3)

Simultaneously activates glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Engineered from the native GIP backbone with amino acid substitutions to confer GCGR and GLP-1R activity.

5.79 nM

0.191 nM

0.794 nM

2.32 nM

0.775 nM

0.0643 nM

Jastreboff AM, et al. N Engl J Med. 2023;389(6):514-526.DOI

NCT04881760; NCT05882045; NCT06354660

CHEMBL5095485

DB18993

D12430

PubChem

NEJM: Jastreboff et al. (2023) — Phase 2 Trial; FDA Drugs@FDA

Retatrutide is an investigational compound not yet approved by FDA or EMA. This listing is for industrial and laboratory research use only. Product information on ECHEMI is provided for sourcing and specification reference. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.